ZPL389A
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $93,021 | 26 | 2 |
| 2017 | $114.00 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $93,135 | 27 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO DETERMINE THE EFFICACY AND SAFETY OF ORAL ZPL389A 3 MG 10 MG 30 MG AND 50 MG CAPSULES ADMINISTERED FOR 16 WEEKS IN SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Novartis Pharmaceuticals Corporation | $62,928 | 0 |
| A MULTI PART STUDY OF ZPL389 A HISTAMINE H4 RECEPTOR ANTAGONIST CONSISTING OF RANDOMIZED SUBJECT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED SINGLE AND MULTIPLE ASCENDING ORAL DOSE STUDY PARTS TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS IN HEALTHY JAPANESE AND NON JAPANESE VOLUNTEERS AND AN OPEN LABEL FOOD EFFECTS STUDY PART IN HEALTHY VOLUNTEERS NONJAPANESE | Novartis Pharmaceuticals Corporation | $28,974 | 1 |
| A MULTI PART STUDY OF ZPL389 A HISTAMINE H4 RECEPTOR ANTAGONIST CONSISTING OF RANDOMIZED SUBJECT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED SINGLE AND MULTIPLE ASCENDING ORAL DOSE STUDY PARTS TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS IN HEALTHY JAPANESE AND NON JAPANESE VOLUNTEERS AND AN OPEN LABEL FOOD EFFECTS STUDY PART IN HEALTHY VOLUNTEERS NONJAPANESE | NOVARTIS PHARMACEUTICALS CORPORATION | $1,232 | 1 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $93,135
- Total Doctors 2
- Transactions 27
About ZPL389A
ZPL389A is a drug associated with $93,135 in payments to 2 healthcare providers, recorded across 27 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2018. In 2018, $93,021 was paid across 26 transactions to 2 doctors.
The most common payment nature for ZPL389A is "Unspecified" ($93,135, 100.0% of total).
ZPL389A is associated with 3 research studies, including "A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO DETERMINE THE EFFICACY AND SAFETY OF ORAL ZPL389A 3 MG 10 MG 30 MG AND 50 MG CAPSULES ADMINISTERED FOR 16 WEEKS IN SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS" ($62,928).